Eileen M. O’Reilly, MD

Eileen M. O’Reilly, MD, a leading expert in Lynch Syndrome and pancreatic cancer, joins to discuss groundbreaking findings on the role of microsatellite instability (MSI) in treatment outcomes. She highlights the importance of MSI as a biomarker for immune checkpoint therapy and the challenges in accurately detecting it. O'Reilly dives into genetic links between Lynch syndrome and pancreatic cancer, exploring critical genes like MLH1 and MSH2. The conversation also touches on future research needs and innovations in detection methods to improve patient care.